Axsome Common Stock Total Equity from 2010 to 2024
| AXSM Stock | USD 97.50 1.18 1.20% |
Common Stock Total Equity | First Reported 2014-12-31 | Previous Quarter 4 K | Current Value 5 K | Quarterly Volatility 1.1 K |
Check Axsome Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Axsome Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 M, Interest Expense of 6.8 M or Selling General Administrative of 234 M, as well as many indicators such as Price To Sales Ratio of 12.69, Dividend Yield of 0.0 or PTB Ratio of 19.88. Axsome financial statements analysis is a perfect complement when working with Axsome Therapeutics Valuation or Volatility modules.
Axsome | Common Stock Total Equity |
Latest Axsome Therapeutics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Axsome Therapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Axsome Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Axsome Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Axsome Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 2,378 | |
| Geometric Mean | 1,968 | |
| Coefficient Of Variation | 55.47 | |
| Mean Deviation | 1,150 | |
| Median | 2,549 | |
| Standard Deviation | 1,319 | |
| Sample Variance | 1.7M | |
| Range | 3.6K | |
| R-Value | 0.91 | |
| Mean Square Error | 329,329 | |
| R-Squared | 0.82 | |
| Slope | 267.77 | |
| Total Sum of Squares | 24.4M |
Axsome Common Stock Total Equity History
About Axsome Therapeutics Financial Statements
Axsome Therapeutics investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Axsome Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 4.3 K | 2.7 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Axsome Therapeutics Correlation against competitors. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.